SalvaRx announces that trading in the Company’s ordinary shares on AIM will be suspended with effect from 7.30 a.m. today.
The suspension is due to the Company not having made an acquisition or acquisitions which would constitute a reverse takeover under AIM Rule 14 (“Reverse Takeover”), or having been re-admitted to trading on AIM as an investing company under the AIM Rules, on or before the date falling six months from the Company’s Annual General Meeting when it was classified as an AIM Rule 15 cash shell.
Trading in the Company’s ordinary shares will remain suspended until the completion of a Reverse Takeover, which requires the publication of an admission document and the approval of such a transaction at a general meeting of the Company, or the Company is re-admitted to trading on AIM as an investing company. If no such transaction is completed within six months the Company’s shares will be cancelled from trading on AIM pursuant to AIM Rule 41.
The Board continues to seek suitable opportunities for a Reverse Takeover and will make a further announcement at the appropriate time.
